Macroglobulinemia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Clinical Trials

Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenstr öm Macroglobulinemia
Conditions:   Waldenstrom's Disease;   Waldenstrom Macroglobulinemia Interventions:   Biological: bone marrow sample;   Biological: blood sample Sponsors:   Centre Hospitalier Universitaire, Amiens;   Centre Henri Becquerel;   University Hospital, Caen;   University Hospital, Lille;   Centre Hospitalier de Lens Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 19, 2021 Category: Research Source Type: clinical trials

Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Conditions:   Lymphoplasmacytic Lymphoma;   Waldenstrom Macroglobulinemia Interventions:   Drug: Ibrutinib;   Biological: Rituximab;   Drug: Venetoclax Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2021 Category: Research Source Type: clinical trials